TABLE 3.
Translocations involving 14q32.33 locus of IGH identified by WGS in addition to defined FISH probes according to IMWG criteria
| Case | Translocation | Comparative analysis by FISH and WGS |
|---|---|---|
| 1 | t(14;19)(q32.33;p13.3) | Similar translocations implicated in B‐cell malignancy [13] |
| 3 | t(1;14)(p35.3;q32.33) | Not previously described but t(1;14)(p35.2;32.33) described in a myeloma cell line [14] |
| 4 | t(1;14)(q21.3;q32.33) | Not described but 1q21.3 locus does cover soluble IL6‐Receptor (OMIM : 614689) |
| 7 | t(8;14)(q24.21;q32.33) | * Translocation juxtaposes MYC and IGH. Poor prognostic marker. [12] |
| 8 | t(2;14) and InDel 14q32.33 | * Translocation partner not identified by FISH, but t(2;14) and insertion Deletion (InDel) at 14q32.33 on WGS |
| 12 | t(14;20)(q32.33;q13.12) | * Translocation t(14;20)(q32;q12) IGH/MAFB associated with poor prognosis. Amplification of 20q13.12 carrying loci of at least two genes with oncogenic potential (WISP2, UBE2C) [8]. |
| 14 | t(10;14)(q26.11;q32.33) | Not previously described. 10q26.11 encompasses FGFR2, mutations of which have been described in MM [15]. |
*
denotes translocation suggested by FISH probes but not identified by that assay – three out of 4 seven cases. Patients 2,5,6,8‐11,13 had no evidence of a translocation involving 14q32.33.